BRAF and metastatic melanoma: Approval of vemurafenib was granted for the treatment of BRAF V600E mutation positive metastatic melanoma based on the results of a pivotal randomized phase 3 trial of vemurafenib vs. dacarbazine, which demonstrated that vemurafenib treatment results in significant improvements in overall survival, progression-free survival, and objective response rate [4].